Drugs / INR101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06472531 | May → Sep 2024 | prostate cancer | Yunhe Pharmaceutical (Tianjin) Co., Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06922903 | Apr 2025 → May 2026 overdue | prostate cancer | Yunhe Pharmaceutical (Tianjin) Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06922929 | Apr 2025 → Apr 2027 expected | prostate cancer | Yunhe Pharmaceutical (Tianjin) Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06922903 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic efficacy and safety of INR101 injection PET/CT imaging” NCT06922903 ↗ |
| Route | Intravenous | “9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT” NCT06472531 ↗ |